Shutter2UIntroduction Teva Pharmaceutical's (NYSE:TEVA) stock is up 69% since I called for a "2024 revival" last December. My excitement centered on the company's progress with its anti-TL1A drug, TEV-48574, as well as its high-flying drugs like Austedo and Ajovy. I last wrote about Teva in May, when I highlighted its Q1 results. Its current ratio creeped under 1 and the 50%+ gains since my December recommendation lowered its return potential in my view. I downgraded the stock to "hold."  Seeking AlphaT ...